Prior work has shown that CR8, a CDK 1, 2, 3, 5, 7, 9 inhibitor and riscovitine derivative, suppressed canonical NFκB activity in CLL [37, 38]. This evidence concerns the gene NFKB1 and B-cell chronic lymphocytic leukemia.